<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0004942'>Aortic aneurysm</z:hpo> and dissection are manifestations of <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e>), a disorder caused by mutations in the gene that encodes fibrillin-1 </plain></SENT>
<SENT sid="1" pm="."><plain>Selected manifestations of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> reflect excessive signaling by the transforming growth factor-beta (TGF-beta) family of cytokines </plain></SENT>
<SENT sid="2" pm="."><plain>We show that <z:hpo ids='HP_0004942'>aortic aneurysm</z:hpo> in a mouse model of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> is associated with increased TGF-beta signaling and can be prevented by TGF-beta <z:chebi fb="68" ids="48706">antagonists</z:chebi> such as TGF-beta-neutralizing antibody or the <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> type 1 receptor (AT1) blocker, <z:chebi fb="0" ids="6541">losartan</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>AT1 antagonism also partially reversed noncardiovascular manifestations of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e>, including impaired alveolar septation </plain></SENT>
<SENT sid="4" pm="."><plain>These data suggest that <z:chebi fb="0" ids="6541">losartan</z:chebi>, a drug already in clinical use for <z:hpo ids='HP_0000822'>hypertension</z:hpo>, merits investigation as a therapeutic strategy for patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> and has the potential to prevent the major life-threatening manifestation of this disorder </plain></SENT>
</text></document>